靶向线粒体复合物I亚基NDUFS2增强FLT3-ITD急性髓系白血病的FLT3抑制疗效
该研究通过代谢聚焦的CRISPR-Cas9增敏筛选、耐药细胞转录组分析及原代样本,发现线粒体复合物I核心亚基NDUFS2在FLT3-ITD AML中高表达且与获得性耐药相关。敲低NDUFS2或药物抑制复合物I可增强gilteritinib活性、诱导凋亡并减轻小鼠白血病负荷,提示NDUFS2是支持FLT3抑制剂耐受的适应性代谢依赖。
要点
- NDUFS2在FLT3-ITD AML获得性耐药中上调并优先表达。
- 敲低NDUFS2损伤复合物I活性并增敏gilteritinib诱导凋亡。
- 复合物I抑制剂IACS-010759增强gilteritinib活性并减轻PDX白血病负荷。
核心结论
- NDUFS2依赖的复合物I活性是支持FLT3抑制剂耐受的适应性代谢依赖,为临床前评估提供机制依据。
研究设计与样本
- 研究采用代谢聚焦的CRISPR-Cas9增敏筛选,整合gilteritinib耐药细胞与原发性样本的转录组分析。
- 在FLT3-ITD AML细胞系、原代FLT3-ITD样本及患者来源异种移植模型中进行验证。
主要发现
- NDUFS2在获得性耐药中上调,并在FLT3-ITD AML中优先表达。
- NDUFS2敲低损害复合物I活性、氧化磷酸化、线粒体膜电位和ATP生成,促进凋亡并增敏gilteritinib。
- IACS-010759增强gilteritinib在FLT3-ITD AML细胞系和原代FLT3-ITD样本中的活性,激活AMPK-PERK-ATF4-CHOP应激信号,促进凋亡并减少PDX模型白血病负荷。
- NDUFS2基因敲低在异种移植模型中延长生存。
- 初步小鼠安全性评估显示在测试的短期给药方案下无 overt 毒性。
临床怎么用
- NDUFS2表达或复合物I活性可能作为FLT3-ITD AML对FLT3 TKI耐受的生物标志物。
- 联合复合物I抑制与gilteritinib是值得进一步临床前评估的增敏策略。
局限性
- 研究为临床前阶段,尚未在患者中验证。
- 小鼠安全性评估仅限短期给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) with FLT3 internal tandem duplication (FLT3-ITD) frequently relapses after FLT3 tyrosine kinase inhibitor (TKI) therapy, highlighting the need to define mechanisms of drug tolerance. Here, we identify the mitochondrial complex I core subunit NDUFS2 as a determinant of FLT3 TKI tolerance in FLT3-ITD AML. A metabolism-focused CRISPR-Cas9 sensitiser screen, integrated with transcriptomic profiling of gilteritinib-resistant cells and primary samples, identified NDUFS2 as upregulated in acquired resistance and preferentially expressed in FLT3-ITD AML. NDUFS2 knockdown impaired complex I activity, oxidative phosphorylation, mitochondrial membrane potential and ATP production, thereby promoting apoptosis and sensitising FLT3-ITD AML cells to gilteritinib. Pharmacologic complex I inhibition with IACS-010759 similarly enhanced gilteritinib activity in FLT3-ITD AML cell lines and primary FLT3-ITD samples, activated AMPK-PERK-ATF4-CHOP stress signalling, promoted apoptosis, and reduced leukaemia burden in a patient-derived xenograft model. Genetic NDUFS2 knockdown also prolonged survival in a xenograft model. A preliminary murine safety assessment showed no overt toxicity under the tested short-term dosing schedule. These findings identify NDUFS2-dependent complex I activity as an adaptive metabolic dependency supporting FLT3 inhibitor tolerance and provide mechanistic insight for further preclinical evaluation.
引用
- Tong X, Chen G, Pan Y, et al. Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication. Leukemia. 2026. PMID: 42897233. doi:10.1038/s41375-026-03170-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。